Jeffrey Rathmell, Ph.D.
- Co-Leader, Host-Tumor Interactions Research Program
- Cornelius Vanderbilt Professor of Immunobiology
- Professor of Pathology, Microbiology and Immunology
- Director, Vanderbilt Center for Immunobiology
Phone
Vanderbilt-Ingram Cancer Center
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
Jeffrey Rathmell, Ph.D.
- Co-Leader, Host-Tumor Interactions Research Program
- Cornelius Vanderbilt Professor of Immunobiology
- Professor of Pathology, Microbiology and Immunology
- Director, Vanderbilt Center for Immunobiology
615-322-3234
jeff.rathmell@vanderbilt.edu
Vanderbilt-Ingram Cancer Center
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
Research Program
Departments/Affiliations
Profile
Education
- Ph.D., Immunology, Stanford University, Stanford, California (1997)
- B.S., Biology, University of Northern Iowa, Cedar Falls, Iowa (1991)
Research Emphasis
Immunometabolism in inflammatory disease, cancer, and anti-tumor immunity
Research Description
There has been a growing appreciation that metabolism is intimately linked to nearly all aspects of cell function and fate. The field of immunometabolism aims to understand how metabolic pathways are regulated in immune cells, how specific metabolic programs alter immune function, and how immunity in turn may influence metabolism. The Rathmell lab focuses on how metabolic pathways influence the function and fate of lymphocytes in inflammatory diseases, anti-tumor immunity, and in leukemia. Our work is highly interdisciplinary and involves the fields of immunology, cancer biology, and cell metabolism. Ultimately the goals of these projects are to exploit the specific metabolic programs of each cell type or activation state to selectively impact effector lymphocytes in inflammatory diseases and leukemic cells in cancer.
Publications
- Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, Kondo J, Coffey RJ, Johnson MO, Rathmell JC, Sharick JT, Skala MC, Smith JA, Berlin J, Washington MK, Nickels ML, Manning HC. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat. Med [print-electronic]. 2018 Feb; 24(2): 194-202. PMID: 29334372, PMCID: PMC5803339, PII: nm.4464, DOI: 10.1038/nm.4464, ISSN: 1546-170X.
- Chen YH, Kratchmarov R, Lin WW, Rothman NJ, Yen B, Adams WC, Nish SA, Rathmell JC, Reiner SL. Asymmetric PI3K Activity in Lymphocytes Organized by a PI3K-Mediated Polarity Pathway. Cell Rep [print-electronic]. 2018 Jan 1/23/2018; 22(4): 860-8. PMID: 29420173, PMCID: PMC5806629, PII: S2211-1247(17)31924-1, DOI: 10.1016/j.celrep.2017.12.087, ISSN: 2211-1247.
- Sugiura A, Rathmell JC. Metabolic Barriers to T Cell Function in Tumors. J. Immunol. 2018 Jan 1/15/2018; 200(2): 400-7. PMID: 29311381, PMCID: PMC5777533, PII: 200/2/400, DOI: 10.4049/jimmunol.1701041, ISSN: 1550-6606.
- Liberti MV, Dai Z, Wardell SE, Baccile JA, Liu X, Gao X, Baldi R, Mehrmohamadi M, Johnson MO, Madhukar NS, Shestov AA, Chio IIC, Elemento O, Rathmell JC, Schroeder FC, McDonnell DP, Locasale JW. A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. Cell Metab [print-electronic]. 2017 Oct 10/3/2017; 26(4): 648-659.e8. PMID: 28918937, PMCID: PMC5629112, PII: S1550-4131(17)30502-8, DOI: 10.1016/j.cmet.2017.08.017, ISSN: 1932-7420.
- Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME, Lee T, Gómez H, Lluch A, Pérez-Fidalgo JA, Wolf MM, Andrejeva G, Rathmell JC, Fesik SW, Arteaga CL. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab. 2017 Oct 10/3/2017; 26(4): 633-647.e7. PMID: 28978427, PMCID: PMC5650077, PII: S1550-4131(17)30560-0, DOI: 10.1016/j.cmet.2017.09.009, ISSN: 1932-7420.
- Andrejeva G, Rathmell JC. Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. Cell Metab. 2017 Jul 7/5/2017; 26(1): 49-70. PMID: 28683294, PII: S1550-4131(17)30346-7, DOI: 10.1016/j.cmet.2017.06.004, ISSN: 1932-7420.
- MacIver NJ, Rathmell JC. Editorial overview: Metabolism of T cells: integrating nutrients, signals, and cell fate [editorial]. Curr. Opin. Immunol [print-electronic]. 2017 Jul 7/3/2017; PMID: 28684058, PII: S0952-7915(17)30101-2, DOI: 10.1016/j.coi.2017.06.002, ISSN: 1879-0372.
- Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ, Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, Irish JM, Rathmell WK, Rathmell JC. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight [print-electronic]. 2017 Jun 6/15/2017; 2(12): PMID: 28614802, PMCID: PMC5470888, PII: 93411, DOI: 10.1172/jci.insight.93411, ISSN: 2379-3708.
- Beckermann KE, Dudzinski SO, Rathmell JC. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev [print-electronic]. 2017 Jun; 35: 7-14. PMID: 28456467, PII: S1359-6101(17)30052-7, DOI: 10.1016/j.cytogfr.2017.04.003, ISSN: 1879-0305.
- Olenchock BA, Rathmell JC, Vander Heiden MG. Biochemical Underpinnings of Immune Cell Metabolic Phenotypes. Immunity. 2017 May 5/16/2017; 46(5): 703-13. PMID: 28514672, PII: S1074-7613(17)30178-4, DOI: 10.1016/j.immuni.2017.04.013, ISSN: 1097-4180.
